XBIO · Insider Trading
Xenetic Biosciences, Inc.
Every open-market purchase and sale reported by XBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-23 | James F Parslow | Interim CEO and CFO | A | +100,000 | — |
| 2026-01-05 | Grigory G. Borisenko | Director | A | +2,500 deriv. | — |
| 2026-01-05 | Firdaus J. Dastoor | Director | A | +2,500 deriv. | — |
| 2026-01-05 | Alexey Andreevich Vinogradov | Director | A | +2,500 deriv. | — |
| 2026-01-05 | Roger D. Kornberg | Director | A | +2,500 deriv. | — |
| 2024-12-13 | Grigory G. Borisenko | Director | A | +2,500 deriv. | — |
| 2024-12-13 | Roger D. Kornberg | Director | A | +2,500 deriv. | — |
| 2024-12-13 | Alexey Andreevich Vinogradov | Director | A | +2,500 deriv. | — |
| 2024-12-13 | Firdaus J. Dastoor | Director | A | +2,500 deriv. | — |
| 2019-01-31 | Dmitry Genkin | Director | J | −29,452 | — |
| 2018-11-30 | Roger D. Kornberg | Director | A | +25,000 deriv. | — |
| 2018-11-30 | James Eric Callaway | Director | A | +25,000 deriv. | — |
| 2018-11-30 | Firdaus J. Dastoor | Director | A | +25,000 deriv. | — |
| 2018-11-30 | Adam Logal | Director | A | +25,000 deriv. | — |
| 2017-11-17 | Firdaus J. Dastoor | Director | A | +25,000 deriv. | — |
| 2017-11-17 | Roger D. Kornberg | Director | A | +25,000 deriv. | — |
| 2017-10-30 | Jeffrey F Eisenberg | CEO | A | +50,000 | — |
| 2017-10-13 | Adam Logal | Director | A | +25,000 deriv. | — |
| 2017-10-13 | James Eric Callaway | Director | A | +25,000 deriv. | — |
| 2017-06-15 | Darlene M Deptula-Hicks | Director | A | +40,000 deriv. | — |
| 2017-06-15 | Michael Scott Maguire | CEO | A | +250,000 deriv. | — |
| 2017-04-04 | James F Parslow | Chief Financial Officer | A | +175,000 deriv. | — |
| 2016-12-23 | Michael Scott Maguire | CEO | A | +250,000 deriv. | — |
| 2016-12-23 | Edward J. Benz JR | Director | A | +25,000 deriv. | — |
| 2016-12-23 | Roger D. Kornberg | Director | A | +25,000 deriv. | — |
| 2016-12-23 | Darlene M Deptula-Hicks | Director | A | +40,000 deriv. | — |
| 2016-12-06 | Jeffrey F Eisenberg | COO | A | +230,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| James F Parslow | Interim CEO and CFO | 100,000 | $193.00K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XBIO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.